Hims & Hers stock skyrockets on landmark Novo Nordisk deal
Hims & Hers Health (NYSE:HIMS) shares surged as much as 52% in early trading Monday after the telehealth leader announced a surprising end to its legal battle with Novo Nordisk.
Under a new strategic collaboration, Hims & Hers will pivot away from its controversial compounded semaglutide offerings to become an official distributor of Novo’s branded GLP-1 blockbusters, Wegovy and Ozempic, starting later this month.
The agreement marks a dramatic de-escalation of a month-long conflict.
In February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers, alleging that the platform’s sale of a $49 compounded weight-loss pill misled consumers and utilized inauthentic active ingredients.
As part of today’s settlement, Novo Nordisk has agreed to dismiss all pending litigation, while Hims & Hers has committed to removing all advertisements for compounded GLP-1 products from its platform.
The partnership will provide Hims & Hers customers with access to authentic, FDA-approved medications at Novo's self-pay prices, which have recently been adjusted to range between $149 and $299 per month to compete with off-brand alternatives.
HIMS stock hit an intraday high of $24.10, adding more than $1.7 billion to the company’s market capitalization in a single session.
Frequently asked questions
More from United States
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
